Brainstorm Cell TherapeuticsBCLI
13F holders, Q4 2024 (December 31)3holders −31
0new positions
16sold out
$2.27avg. 13F price*
At the end of Q4 2024, 3 institutions reported holding Brainstorm Cell Therapeutics (BCLI) in their 13F filings, down 31 from Q3 2024. 0 opened new positions and 16 sold out. The largest holders were Liberty Wealth Management LLC ($51K), Weaver Consulting Group ($35K) and VSM Wealth Advisory, LLC ($272).
- Company
- Brainstorm Cell Therapeutics
- CUSIP
- 10501E201
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 16 | $1.7M |
All 13F filers, Q3 2024 → Q4 2024: 7,972,585 shares sold, net −7,972,585 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Liberty Wealth Management LLC | 0.01% | Reduce -93.3% | 22,666 | $51K |
| Weaver Consulting Group | 0.01% | Reduce -93.3% | 15,623 | $35K |
| VSM Wealth Advisory, LLC | 0.00% | — | 120 | $272 |
"% of holder's portfolio" is BCLI's weight in each manager's 13F, not the share of Brainstorm Cell Therapeutics the manager owns.